Clinical trial · Interventional
Effects of Growth Hormone on Difficult Ventilator Weaning Patients
Role of Recombinant Human Growth Hormone rHGH in Weaning of Prolonged Ventilation After Major Abdominal Cancer Surgeries.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Major abdominal surgeries may be followed by postoperative pulmonary complications (PPCs). These complications are common and can cause significant morbidity and mortality. Major operations are followed by acute respiratory insufficiency (RI) in 3%-27.4%, which causes prolonged hospital stay, high patient costs, high mortality rate and lower survival rates. The most crucial pulmonary postoperative complication is the prolonged mechanical ventilation and difficult weaning.The rHGH is a synthetic metabolic hormone which improves synthesis of protein, corrects hypoalbumenia, reverses negative nitrogen balance, improves patient nutrition, improves wound healing and promotes recovery of respiratory muscle function. When used for weaning from mechanical ventilation, rHGH reducess the duration of mechanical ventilation time, ICU admission period, incidence of VAP \& ICU mortality.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Mechanical Ventilation Complication | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Control | Other | — | UNRESOLVED |
| Recombinant human growth hormone | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Recombinant human growth hormone
- description
- Patients who received growth hormone immediately after tracheostomy.
- interventionNames
- Drug: Recombinant human growth hormone
- type
- ACTIVE_COMPARATOR
- label
- Control
- description
- Patients who did not receive growth hormone and followed the conventional weaning trials
- interventionNames
- Other: Control
Primary outcomes (1)
- measure
- The effect of rHGH on the mechanical ventilation time in patients underwent abdominal cancer surgery and needed postoperative mechanical ventilation for a long period
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patients undergoing major abdominal cancer surgeries. * Patients requiring prolonged postoperative ventilation. * Patients with multiple failed trials of mechanical ventilation weaning. * ASA I and II patients. Exclusion Criteria: * History of chronic cardiac,renal or respiratory illness. * Septic or septic shock patients on inotropic supports. * Fully alert and Conscious patients. * ASA 3 and 4.
References
Publications (0)
Data not yet available